Macular Edema and Macular Degeneration Market Outlook Through 2030: Understanding The Growth Opportunity

Macular Edema and Macular Degeneration Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Macular Edema and Macular Degeneration Market Forecast: What Value Will The Market Reach By 2030?

The market size for macular edema and macular degeneration has experienced robust growth in recent years. This market is expected to expand from $10.33 billion in 2025 to $11.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical expansion can be attributed to the rising prevalence of diabetes and retinal disorders, an aging population with elevated vision impairment risks, the clinical effectiveness of anti-VEGF injections, increased awareness of macular diseases, and the proliferation of ophthalmology clinics.

The macular edema and macular degeneration market size is anticipated to experience robust expansion over the coming years, with projections indicating a rise to $14.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period is primarily driven by factors such as the escalating global diabetic population, increased screening for retinal diseases, a growing preference for minimally invasive eye treatments, wider accessibility to advanced ophthalmic care, and elevated healthcare spending directed towards vision preservation. Significant trends expected during this period include the increasing adoption of anti-VEGF based therapies, a heightened demand for early diagnosis and intervention, the expanding utilization of combination drug and laser therapies, a growing emphasis on managing diabetic eye complications, and the continued expansion of outpatient and clinic-based eye care services.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=49200546&type=smp&name=Macular%20Edema%20and%20Macular%20Degeneration%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Macular Edema and Macular Degeneration Market Growth Drivers: What’s Behind The Acceleration?

The increasing number of individuals with diabetes is anticipated to propel the growth of the macular edema and macular degeneration market. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. This condition damages the blood vessels within the eye, potentially resulting in macular edema and macular degeneration. For instance, in June 2024, data from The National Health Service (NHS England), a UK-based publicly funded healthcare system, indicated a substantial rise in pre-diabetes cases. In 2023, the NHS in England identified 3,615,330 individuals with pre-diabetes, marking an 18% increase from 3,065,825 in 2022. Furthermore, among individuals younger than 40, cases saw a surge of nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Therefore, the expanding diabetes population is a significant driver for the growth of the macular edema and macular degeneration market.

Macular Edema and Macular Degeneration Market Segmentation: How Does The Market Break Down By Category?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy

Macular Edema and Macular Degeneration Market Trends: What’s Defining The Industry’s Next Phase?

Major companies within the macular edema and macular degeneration market are prioritizing the creation of innovative solutions, such as continuous-delivery ocular implants, aimed at lessening treatment demands, enhancing patient adherence, and delivering more consistent long-term therapeutic results. Continuous-delivery ocular implants are compact, replenishable devices inserted into the eye that gradually release medication over several months, thereby aiding patients by reducing the need for frequent injections and providing stable, prolonged treatment for retinal conditions. For example, in February 2025, F. Hoffmann-La Roche Ltd, a biotechnology company headquartered in Switzerland, obtained U.S. Food and Drug Administration (FDA) approval for Susvimo, a refillable ocular implant designed to deliver the anti-VEGF drug ranibizumab for treating diabetic macular edema (DME). Susvimo is engineered as a long-acting, surgically placed reservoir that continuously releases a tailored formulation of ranibizumab, thereby sustaining therapeutic drug levels for extended durations. Unlike standard anti-VEGF intravitreal injections, which often demand monthly or bi-monthly administration, Susvimo provides a refill-exchange interval of roughly six months, significantly reducing the treatment burden for patients. Its sustained-delivery approach improves adherence, streamlines clinical operations, and offers durable anatomical and visual benefits for individuals suffering from chronic retinal disease.

Macular Edema and Macular Degeneration Market Competitive Overview And Top Companies

Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.

View The Full Macular Edema and Macular Degeneration Market Report:

https://thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Macular Edema and Macular Degeneration Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model